Linked Life Data

19854590

Source:http://linkedlifedata.com/resource/pubmed/id/19854590

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2010-4-23
pubmed:abstractText
The aims of this multicentre open-label study was to evaluate the pharmacokinetics of linezolid in patients with burn injury above 20 % BSA and to compare them with healthy volunteers, matched in age, sex and weight. After a single 600 mg IV dose of linezolid, multiple blood and urine samples were taken from subjects, in order to determine linezolid concentrations, using a HPLC assay. C(max) and volume of distribution at steady state were not different between the two groups. Values describing clearance were altered in burns, leading to a reduction by half in AUC in these patients (42.5 versus 98.1 mghL(-1)). The enhancement of clearance was due to which of non renal clearance (323+/-191 versus 80.4+/-27.5 mLmin(-1)). We conclude that pharmacokinetics of linezolid are altered in burn patients, in a magnitude sufficient that linezolid concentration may be subtherapeutic in some patients and we suggest that the dosage interval may need to be decreased in this patient population.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1768-3114
pubmed:author
pubmed:copyrightInfo
Copyright 2009 Elsevier Masson SAS. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
58
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
e27-31
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
[Pharmacokinetic evaluation of linezolid in patients with major thermal injuries].
pubmed:affiliation
Centre de traitement des brûlés, CHU de Nantes, 44093 Nantes cedex 1, France. ronan.lefloch@chu-nantes.fr
pubmed:publicationType
Journal Article, English Abstract, Controlled Clinical Trial, Multicenter Study